Bristol Myers Squibb Company (NYSE:BMY) Short Interest Update

Bristol Myers Squibb Company (NYSE:BMY) saw a significant drop in short interest in January. As of January 30th, there was short interest totaling 29,894,882 shares, a drop of 19.1% from the January 15th total of 36,975,176 shares. Based on an average trading volume of 12,741,067 shares, the days-to-cover ratio is currently 2.3 days. Currently, 1.5% of the company’s stock are sold short. Currently, 1.5% of the company’s stock are sold short. Based on an average trading volume of 12,741,067 shares, the days-to-cover ratio is currently 2.3 days.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Leerink Partners increased their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Scotiabank reissued a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $59.20.

Bristol Myers Squibb Price Performance

BMY stock traded up $0.78 during trading on Monday, hitting $60.64. The company had a trading volume of 10,818,863 shares, compared to its average volume of 12,992,969. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company has a fifty day moving average price of $55.50 and a two-hundred day moving average price of $49.61. The company has a market cap of $123.49 billion, a P/E ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same period in the previous year, the business posted $1.67 EPS. The business’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts expect that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date was Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Institutional Trading of Bristol Myers Squibb

Several institutional investors and hedge funds have recently added to or reduced their stakes in BMY. Oarsman Capital Inc. grew its position in shares of Bristol Myers Squibb by 4.1% during the 4th quarter. Oarsman Capital Inc. now owns 39,306 shares of the biopharmaceutical company’s stock worth $2,120,000 after buying an additional 1,532 shares during the period. OMERS ADMINISTRATION Corp boosted its stake in Bristol Myers Squibb by 0.6% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 124,513 shares of the biopharmaceutical company’s stock valued at $6,716,000 after acquiring an additional 802 shares during the last quarter. Sofinnova Investments Inc. acquired a new stake in Bristol Myers Squibb during the 4th quarter worth $81,611,000. Trustco Bank Corp N Y raised its position in shares of Bristol Myers Squibb by 7.0% during the 4th quarter. Trustco Bank Corp N Y now owns 6,121 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 400 shares during the last quarter. Finally, USS Investment Management Ltd lifted its stake in shares of Bristol Myers Squibb by 1.8% in the 4th quarter. USS Investment Management Ltd now owns 362,511 shares of the biopharmaceutical company’s stock valued at $19,559,000 after purchasing an additional 6,259 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.